About
Company Overview
Management Team
Board of Directors
Scientific Advisory Board
Partnering
Careers
CBD
Programs
Overview
GvHD Program
Preclinical Programs
News
Investors
Investor Overview
Press Releases
Company Information
SEC Filings
Stock Information
Corporate Governance
Contact
About
Company Overview
Management Team
Board of Directors
Scientific Advisory Board
Partnering
Careers
CBD
Programs
Overview
GvHD Program
Preclinical Programs
News
Investors
Investor Overview
Press Releases
Company Information
SEC Filings
Stock Information
Corporate Governance
Contact
Press Releases
Menu
Overview
Press Releases
Company Information
Stock Information
SEC Filings
Corporate Governance
Recent Press Releases
Kalytera Submits Phase 2 Study Protocol to IRBs for Cannabidiol in the Prevention of Graft versus Host Disease
August 14, 2017
Kalytera Announces Management Changes and Expansion of Leadership Team
June 22, 2017
Kalytera Reports First Quarter 2017 Financial Results
May 31, 2017
Kalytera Announces Changes to its Board of Directors
May 26, 2017
Kalytera Reports FY 2016 Results; Provides Corporate Update and 2017 Outlook
May 2, 2017
Kalytera Identifies Sites for Planned GvHD Clinical Trials
April 25, 2017
Kalytera Applies for $5 Million R&D Grant from IIA
April 17, 2017
View all News and Insights
Browse by Year
2017
2016
2015
